Advanced search
Publication Cover
Expert Review of Hematology Volume 8, 2015 - Issue sup1
Submit an article Journal homepage
1,771
Views
0
CrossRef citations to date
0
Altmetric
Abstract Book

3rd Mediterranean Multidisciplinary Course on Iron Anemia

April, 17th–18th 2015, Rome, Italy

Pages S1-S32 | Published online: 19 May 2015

References

  • Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-23.
  • Muñoz M, Garcia-Erce JA, Remacha AF. Disorders of iron metabolism. Part II: iron deficiency and iron overload. J Clin Pathol 2011;64:287-96
  • Theurl I, Aigner E, Theurl M, et al. Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 2009;113:5277-86.
  • Muñoz M, García-Vallejo JJ, Sempere JM, et al. Acute phase response in patients undergoing lumbar spinal surgery: modulation by perioperative treatment with naproxen and famotidine. Eur Spine J 2004;13:367-73.
  • Van Iperen CE, Kraaijenahgen RJ, et al. Iron metabolism and erythropoiesis after surgery. Br J Surg 1998;85:41-5.
  • Muñoz M, Garcia-Erce JA, Remacha AF. Disorders of iron metabolism. Part 1: molecular basis of iron homoeostasis. J Clin Pathol 2011;64:281-6.
  • Bregman DB, Morris D, Koch TA, et al. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol 2013;88:97-101.
  • Yuan L, Geng L, Ge L, et al. Effect of iron liposomes on anemia of inflammation. Int J Pharm 2013;454:82-9.
  • Ganz T. Systemic iron homeostasis. Physiol Rev 2013;93:1721-41.
  • Lindgren S, Wikman O, Befrits R, et al. Intravenous iron sucrose is superior to oral iron sulphate for correcting anaemia and restoring iron stores in IBD patients: A randomized, controlled, evaluator-blind, multicentre study. Scand J Gastroenterol 2009;44:838-45.
  • Evstatiev R, Marteau P, Iqbal T, et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology 2011;141:846-53.e1-2.
  • Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol 2008;103:1182-92.
  • Reinisch W, Staun M, Tandon RK, et al. A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED). Am J Gastroenterol 2013;108:1877-88.
  • Khalil A, Goodhand JR, Wahed M, et al. Efficacy and tolerability of intravenous iron dextran and oral iron in inflammatory bowel disease: a case-matched study in clinical practice. Eur J Gastroenterol Hepatol 2011;23:1029-35.
  • Calvet X, Ruíz MÀ, Dosal A, et al. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency. PLOS One 2012;7:e45604.

References

  • Cella D, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 2003;14:511-9.
  • Cella D, Stone AA. Health-related quality of life measurement in oncology: Advances and opportunities. Am Psychol 2015;70:175-85.
  • Sankaran VG, Weiss MJ. Anemia: progress in molecular mechanisms and therapies. Nat Med 2015;21:221-30.
  • Tessitore N, Solero GP, Lippi G, et al. The role of iron status markers in predicting response to intravenous iron in hemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 2001;16:1416–23.
  • Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alfa. J Clin Oncol 2008;25:1619-25.
  • Ludwig H, Müldür E, Endler G, Hübl W. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol 2013;24:1886-92.
  • Auerbach M. Should intravenous iron be the standard of care in oncology? J Clin Oncol 2008;25:1579-81.
  • Petrelli F, Borgonovo K, Cabiddu M, et al. Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. J Cancer Res Clin Oncol 2012;138:179-87.
  • Pedrazzoli P, Rosti G, Secondino S, Siena S. Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia. Cancer 2009;115:1169-73.
  • Yuan L, Geng L, Ge L, et al. Effect of iron liposomes on anemia of inflammation. Int J Pharm 2013;454:82-9.

References

  • Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012;12:CD003407.
  • Petrelli F, Borgonovo K, Cabiddu M, et al. Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. J Cancer Res Clin Oncol 2012;138(2):179-87.
  • Lin L, Valore EV, Nemeth E, et al. Iron transferrin regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin and BMP2/4. Blood 2007;110(6):2182-9.
  • Muckenthaler M, Roy CN, Custodio AO, et al. Regulatory defects in liver and intestine implicate abnormal hepcidin and Cybrd1 expression in mouse hemochromatosis. Nat Genet 2003;34(1):102-7.
  • Meynard D, Babitt JL, Lin HY. The liver: conductor of systemic iron balance. Blood 2014;123(2):168-76.
  • Ganz T.Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003;102(3):783-8.
  • Frazer DM, Inglis HR, Wilkins SJ, et al. Delayed hepcidin response explains the lag period in iron absorption following a stimulus to increase erythropoiesis. Gut 2004;53(10):1509-15.
  • Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducingits internalization. Science 2004;306(5704):2090-3.
  • Smith RE Jr, Aapro MS, Ludwig H, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008;26(7):1040-50.
  • Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25(9):1027-32.
  • Talebi TN, Stefanovic A, Merchan J, et al. Sunitinib-induced microangiopathic hemolytic anemia with fatal outcome. Am J Ther 2012;19(4):e143-5.
  • Bevacizumab + sunitinib: microangiopathic haemolytic anemia. A serious drug interaction between 2 cancer drugs. Prescrire Int 2009;18(102):165.
  • Price J, Shaarbaf R, Wood L. Sunitinib causes macrocytosis in patients with advanced renal cell carcinoma. Curr Oncol 2010;17(2):30-3.
  • Rini BI, Choueiri TK, Elson P, et al. Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma. Cancer 2008;113(6):1309-14.
  • Jain R, Mathew P, Wood CG, et al. Sunitinib-induced acute hemolysis without hypertension: a case report. Clin Genitourin Cancer 2008;6(2):122-3.
  • Schallier D, Trullemans F, Fontaine C, et al. Tyrosine kinase inhibitor-induced macrocytosis. Anticancer Res 2009;29(12):5225-8.
  • Billemont B, Izzedine H, Rixe O. Macrocytosis due to treatment with sunitinib. N Engl J Med 2007;357(13):1351-2.
  • Gratwohl A, John L, Baldomero H, et al. FLT-3 ligand provides hematopoietic protection from total body irradiation in rabbits. Blood 1998;92(3):765-9.
  • Barni S, Cabiddu M, Guarneri P, et al. The risk for anemia with targeted therapies for solid tumors. Oncologist 2012;17(5):715-24.
  • Schutz FA, Je Y, Azzi GR, et al. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol 2011;22(6):1404-12.
  • Sher A, Wu S. Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis. Acta Oncol 2011;50(7):997-1005.
  • Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369(8):722-31.
  • Santoni M, Conti A, Massari F, et al. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials. Int J Cancer 2015;136(1):1-10.
  • Kollmannsberger C, Bjarnason G, Burnett P, et al. Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist 2011;16(5):543-53.
  • Funakoshi T, Latif A, Galsky MD. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis. Cancer Treat Rev 2013;39(7):818-30.

Reference

  • Muñoz M, García-Erce JA, Cuenca J, Bisbe E, Naveira E; AWGE (Spanish Anemia Working Group). On the role of iron therapy for reducing allogeneic blood transfusion in orthopaedic surgery. Blood Transfus 2012;10(1):8-22
  • Spahn DR. Anemia and patient blood management in hip and knee surgery. A systematic review of the literature. Anesthesiology 2010; 113:482-95.
  • Canillas F, Gómez-Ramírez S, García-Erce JA, Pavía-Molina J, Gómez-Luque A, Muñoz M. “Patient blood management” in orthopaedic surgery. Rev Esp Cir Ortop Traumatol 2015;59(3):137-49
  • García-Erce JA, Cuenca J, Solano VM. [Predictive factors for transfusion requirements in patients over 65 years old with subcapital hip fracture]. Med Clin (Barc) 2003;120(5):161-6
  • Muñoz M, Gómez-Ramírez S, García-Erce JA. Implementing Patient Blood Management in major orthopaedic procedures: orthodoxy or pragmatism? Blood Transfus 2014;12(2):146-9
  • García Erce JA, Peral García AI. New paradigms in patient blood management in surgery. Cir Esp 2015;93(1):59-61.
  • Patient BloodManagement. (http://www.aabb.org/pbm/Pages/default.aspx) ( last access March 2015)
  • Leal-Noval SR, Muñoz M, Asuero M, Contreras E, García-Erce JA, Llau JV, Moral V, Páramo JA, Quintana M; Spanish Expert Panel on Alternatives to Allogeneic Blood Transfusion. Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the “Seville Document”. Blood Transfus 2013;11(4):585-610.
  • Canadian Society of Hematology. Five Things Physicians and Patients Should Question. http://www.choosingwiselycanada.org/recommendations/hematology/ ( last access March 2015)
  • American Association of Blood Banks. Five Things Physicians and Patients Should Question. http://www.choosingwisely.org/doctor-patient-lists/american-association-of-blood-banks/ ( last access March 2015)
  • Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CA, De Robertis E, Filipescu DC, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013 Jun;30(6):270-382.
  • Lidder PG, Sanders G, Whitehead E, et al. Pre-operative oral iron supplementation reduces blood transfusion in colorectal surgery - a prospective, randomised, controlled trial. Ann R Coll Surg Engl 2007; 89: 418-21.
  • Okuyama M, Ikeda K, Shibata T, et al. Preoperative iron supplementation and intraoperative transfusion during colorectal cancer surgery. Surg Today 2005;35:36-40.
  • Cuenca J, García-Erce JA, Martínez F, Cardona R, Pérez-Serrano L, Muñoz M. Preoperative haematinics and transfusion protocol reduce the need for transfusion after total knee replacement. Int J Surg 2007;5(2):89-94.
  • Goodnough LT, Maniatis A, Earnshaw P, Benoni G, Beris P, Bisbe E, et al. Detection, evaluation, and management of preoperative anemia in the elective orthopaedic surgical patient: NATA guidelines. Br J Anaesth 2011;106:13-22.

References

  • Zumbrennen-Bullough K, Babitt JL. The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients. Nephrol Dial Transplant 2014;29:263-73
  • Kalantar-Zadeh K, Lee GH, Miller JE, et al. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis 2009;53:823–34.
  • Cancelo-Hidalgo MJ, Castelo-Branco C, Palacios S, et al. Tolerability of different oral iron supplements: a systematic review. Curr Med Res Opin 2013;29:291–303
  • Kortman GA, Raffatellu M, Swinkels DW, et al. Nutritional iron turned inside out: intestinal stress from a gut microbial perspective. FEMS Microbiol Rev 2014;38:1202-34
  • Sabatino A, Regolisti G, Brusasco I, et al. Alterations of intestinal barrier and microbiota in chronic kidney disease. Nephrol Dial Transplant. 2014 Sep 4. In press
  • Radulescu S, Brookes MJ, Salgueiro P, et al. Luminal iron levels govern intestinal tumorigenesis after apc loss in vivo. Cell Rep 2012;2:270–82
  • Nastou D, Fernández-Fernández B, Elewa U, et al. Next-generation phosphate binders: focus on iron-based binders. Drugs 2014;74:863-77
  • Albaramki J, Hodson EM, Craig JC, et al. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev 2012;1:CD007857
  • KDIGO clinical practice guidelines for anemia in chronic kidney disease. Kidney Int 2012;Suppl 2:279-335
  • Macdougall IC, Bock AH, Carrera F, et al. FIND-CKD Study Investigators. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anemia. Nephrol Dial Transplant. 2014; 29: 2075-84
  • Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ 2013; 347:f4822
  • Fishbane S, Mathew A, Vaziri ND. Iron toxicity: relevance for dialysis patients. Nephrol Dial Transplant. 2014;29: 255-9

References

  • Vaupel P, Mayer A, Höckel M. Impact of hemoglobin levels on tumor oxygenation: the higher, the better? Strahlenther Onkol Organ Dtsch Röntgenges Al. febbraio 2006;182(2):63–71.
  • Kumar P. Impact of anemia in patients with head and neck cancer. The Oncologist. 2000;5 Suppl 2:13–8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.